◼ Archived
Business
Kyverna ‘resetting conversation’ with 1-year miv-cel data as autoimmune CAR-T peers hit safety snags
Kyverna advances its cell therapy toward an FDA submission as new one-year durability data emerges.
Kyverna
1 trends tracked about this subject — the full history, oldest to newest below.